In individuals with anorexia nervosa, psilocybin therapy comes with specific risks and concerns; but an encouraging phase 1 trial underscores the necessity for more research into classic psychedelics to address the urgent need for effective treatments.
References
Treasure, J. et al. Nat. Rev. Dis. Primer 1, 15074 (2015).
Knatz Peck, S. et al. Nat. Med. https://doi.org/10.1038/s41591-023-02455-9 (2023).
Goodwin, G. M. et al. N. Engl. J. Med. 387, 1637–1648 (2022).
Moreno, F. A., Wiegand, C. B., Taitano, E. K. & Delgado, P. L. J. Clin. Psychiatry 67, 1735–1740 (2006).
Majić, T., Schmidt, T. T. & Gallinat, J. J. Psychopharmacol. 29, 241–253 (2015).
Weinert, T. et al. Eur. Arch. Psychiatry Clin. Neurosci. 273, 209–217 (2023).
Olson, D. E. Biochemistry 61, 127–136 (2022).
Walton, E. et al. Biol. Psychiatry 92, 730–738 (2022).
Boehm, I. et al. Front. Behav. Neurosci. 8, (2014).
Gattuso, J. J. et al. Int. J. Neuropsychopharmacol. 26, 155–188 (2023).
Seidel, M. et al. Eur. Child Adolesc. Psychiatry 25, 1207–1216 (2016).
Bulik, C. M. et al. Nat. Neurosci. 25, 543–554 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial or non-financial interests related to the topic.
Rights and permissions
About this article
Cite this article
Majić, T., Ehrlich, S. Psilocybin for the treatment of anorexia nervosa. Nat Med 29, 1906–1907 (2023). https://doi.org/10.1038/s41591-023-02458-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02458-6
- Springer Nature America, Inc.